Biotech Cat (@BiotechCat) header
Biotech Cat (@BiotechCat) profile picture

Biotech And More | Not Investment Advice | Will Make Mistakes, Always Learning | DMs Open

Joined April 2022
Photo by Biotech Cat (@BiotechCat)Photo by Biotech Cat (@BiotechCat)Photo by Biotech Cat (@BiotechCat)Photo by Biotech Cat (@BiotechCat)Photo by Biotech Cat (@BiotechCat)Photo by Biotech Cat (@BiotechCat)Photo by Biotech Cat (@BiotechCat)Photo by Biotech Cat (@BiotechCat)Photo by Biotech Cat (@BiotechCat)Photo by Biotech Cat (@BiotechCat)
Checking in on a few of my past calls 🧵
1
5
4,884
Who remembers this thread? @Biopharmaddict
You’re unable to view this Post because this account owner limits who can view their Posts. Learn more
1
2
16
4,292
Biotech Cat retweeted
Sometimes when an analyst or investor sees the COO of a public biotech company spending a couple of weeks hiking to Everest basecamp while its stock is $0.30, they think that maybe they should be working harder to fix the situation the company is in.
16
8
10
141
86,661
TRAITS OF A GOOD ANALYST (1/2) Over the past several years I’ve had 6 analysts who at some point reported me, and have interacted with countless more.  These are the traits I’ve found to be most correlated with long term success. They probably aren’t what you think. A 🧵 What I don’t care about: Where you went to school, what banking program you did (or didn’t do), your test scores, your stock picking ability (initially). These are markers traditionally associated with success that IMO have little bearing on being a good analyst. What I do care about: An analyst’s job is to do excellent research in an intellectually honest, time efficient manner, and to communicate their findings clearly, succinctly, and accurately. Ideally they do this with as little oversight and friction as possible, allowing the fund to make more and better investments than they could without them. 1. Passion Some people love investing and researching companies - they just find it fun. If you find something fun, you tend to work harder at it and be better at it. Passion is also easy to screen for in a resume / interview. As a PM, it’s also energizing to work with passionate people who love the work. 2. Curiosity A lot of investing is asking the right questions. Curious people ask more and better questions. They go the extra distance vs. checking a box.  It’s often very small or incremental insights that make an idea or research better than another. 3. Humility / Open-mindedness - arrogance is a killer in this business.  On balance, smart people with “good” resumes tend to be more arrogant. Confirmation bias sinks analysts and sinks funds. Any hint of arrogance / confirmation bias is an automatic pass for us. 4. Attention to detail - careless mistakes in modeling erode trust and offset a lot of good and thoughtful work. They also require much more managerial oversight. It’s hard to be a good analyst if you frequently make mistakes or miss things. 5.  Trust / honesty  - PMs hire analysts to get leverage on their time - if your PM can’t trust you or your work, there is nowhere to go.  Admit your mistakes and make sure what you show the PM is accurate, even if it takes longer. Once trust is eroded it’s hard to get it back.
17
63
6
633
103,760
Hope everyone's JPM goes well Taking it lowkey this year Long $XBI this year but don't think it will be a major outperform year Portfolio of 20-30 carefully picked names, all with tangible catalysts and no data deserts, and edge in predicting binary, will do best
2
14
2,504
If you are the only specialist of your peers to have talked 1-on-1 with 30 KOLs and found a repeatable pattern or some insight into ongoing trial progress then you deserve to make money on the name
6
1,195
Is $MDGL launch beating estimates?
3
2
14
2,463
Just to clarify...the YTE names will just trade sideways until validating Ph1b data and then go parabolic? :)
3
1,032
hey so this is crazy
2
889
#JPM24 I'm investing less in bio nowadays, but who put Abivax on Thurs at 10:30AM last time slot :(
1
1
1,003
That $VIX spike is crazy...
1
1
808
I know there are traditional factors to understand if an economy is overheated but a quality market rally, companies pushing price with same or more demand, and a recent rate cut that probably wasn't needed...yes it is ok if the next rate cut is delayed for a while
680
this is creative and interesting
6
1,340
Congrats to $ACLX bulls; great stock to own up and to the right Paradigm been holding for number of quarters
1
802
$PSTX 14d-9 out. A long negotiation process with Roche post-partnership. Nice milly sev for <1yr as CEO! 03/09/21: PSTX and Roche signed NDA for potential collaboration. 08/2022: PSTX and Roche entered collaboration agreement, amended multiple times. 04/2023: PSTX received unsolicited acquisition proposal; reached out to Roche. 08/08/23: Astellas invested $50M in PSTX, gaining strategic rights. 08/27/24: Roche offered $5.75/share; PSTX rejected as undervalued. 09/12/24: Roche revised to $7.50/share + CVR; PSTX rejected. 11/01/24: Roche offered $9.00/share + CVR; further negotiations followed. 11/07/24: Roche made final $9.00/share + CVR offer; PSTX advanced talks. 11/25/24: PSTX Board approved Merger Agreement with Roche. 11/26/24: PSTX and Roche announced Merger Agreement.
2
10
3,044
I used to think $PSTX had some of the best CAR-T technology during the biotech bubble; differentiated, long persistence, unbelievable case studies. No one cared about the name. Once management rotated, I was uncertain about future and sold at cost. I should have held!
3
1
12
1,794
$VKTX Brian Commentary
4
6
53
11,886
Price discovery of names today is interesting Also seeing quite a dispersion in fund returns YTD, and not even to do with exposures. Some absolutely killing it. @PCM_bio
1
1,240